Answers are grounded in this paper and cite their sources.
Real-world study finds zonisamide effectively improves outcomes in children with refractory epilepsy, supporting its use in this population.
Adjunctive zonisamide provides sustained efficacy and favorable tolerability in children with DEE/EE, including young children < 6 years and highly drug-resistant cases. Gender and prior treatment history predict long-term efficacy, supporting its reliable risk-benefit profile for refractory epilepsy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: